Brief: VBI Vaccines Presents Updated Phase 2A Tumor Response And Overall Survival Data For Vbi-1901
06/06/2022 13:29
June 6 (Reuters) - VBI Vaccines Inc VBIV.O :
* VBI VACCINES PRESENTS UPDATED PHASE 2A TUMOR RESPONSE AND
OVERALL SURVIVAL DATA FOR VBI-1901 IN RECURRENT GBM AT THE 2022
ASCO ANNUAL MEETING
* VBI VACCINES INC- MEDIAN OVERALL SURVIVAL AND 18-MONTH
OVERALL
SURVIVAL DATA CONTINUE TO SHOW IMPROVEMENTS OVER HISTORICAL
CONTROLS
* VBI VACCINES INC- ONE PATIENT REMAINS ON PROTOCOL
PROGRESSION-FREE BEYOND TWO YEARS, WITH A SUSTAINED 93% TUMOR
REDUCTION RELATIVE TO BASELINE
* VBI VACCINES- RECURRENT GBM: RANDOMIZED, CONTROLLED
EVALUATION
WITH POTENTIAL TO SUPPORT ACCELERATED APPROVAL APPLICATION
EXPECTED TO INITIATE Q3 2022
* VBI VACCINES INC- PRIMARY GBM: RANDOMIZED, CONTROLLED
EVALUATION
IN FRONTLINE SETTING EXPECTED TO INITIATE IN Q4 2022
Source text for Eikon: ID:nBwbsV1n6a
Further company coverage: VBIV.O
((reuters.briefs@thomsonreuters.com;))
Recent news on VBI Vaccines
See all newsBrief: VBI Vaccines Provides Update On Its Restructuring Proceedings
Brief: Vbi Vaccines Announces New Tumor Response Data From Ongoing Randomized Controlled Phase 2B Study Of Vbi-1901 In Recurrent Glioblastoma Patients
VBI Vaccines Inc reports results for the quarter ended in March - Earnings Summary
Brief: VBI Vaccines Says Entered At Market Offering Deal For Gross Proceeds Of Up To $8.5 Mln
Brief: VBI Vaccines Q1 Adjusted EPS USD -0.55